-
Something wrong with this record ?
Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs
C. Schmidt, T. Babu, H. Kostrhunova, A. Timm, U. Basu, I. Ott, V. Gandin, V. Brabec, D. Gibson
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Cell Line MeSH
- Cricetulus MeSH
- Carbonic Anhydrase IV chemistry metabolism MeSH
- Humans MeSH
- Ligands MeSH
- Molecular Structure MeSH
- Organoplatinum Compounds chemical synthesis chemistry pharmacology MeSH
- Prodrugs chemical synthesis chemistry pharmacology MeSH
- Prohibitins MeSH
- Cell Proliferation drug effects MeSH
- Antineoplastic Agents chemical synthesis chemistry pharmacology MeSH
- Drug Screening Assays, Antitumor MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
"Multi-action" Pt(IV) derivatives of cisplatin with combretastatin A4 (CA4) bioactive ligands that are conjugated to Pt(IV) by carbonate are unique because the ligand (IC50 < 10 nM) is dramatically 1000-folds more cytotoxic than cisplatin in vitro. The Pt(IV)-CA4 prodrugs were as cytotoxic as CA4 itself, indicating that the platinum moiety probably plays an insignificant role in triggering cytotoxicity, suggesting that the Pt(IV)-CA4 complexes act as prodrugs for CA4 rather than as true multi-action prodrugs. In vivo tests (Lewis lung carcinoma) show that ctc-[Pt(NH3)2(PhB)(CA4)Cl2] inhibited tumor growth by 93% compared to CA4 (67%), cisplatin (84%), and 1:1:1 cisplatin/CA4/PhB (85%) while displaying <5% body weight loss compared to cisplatin (20%) or CA4 (10%). In this case, and perhaps with other extremely potent bioactive ligands, platinum(IV) acts merely as a self-immolative carrier triggered by reduction in the cancer cell with only a minor contribution to cytotoxicity.
Dipartimento di Scienze del Farmaco Universita di Padova Via Marzolo 5 35131 Padova Italy
Institute for Drug Research School of Pharmacy The Hebrew University 91120 Jerusalem Israel
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004976
- 003
- CZ-PrNML
- 005
- 20230425171829.0
- 007
- ta
- 008
- 230418s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.1c00706 $2 doi
- 035 __
- $a (PubMed)34342437
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Schmidt, Claudia $u Institute for Drug Research, School of Pharmacy, The Hebrew University, 91120 Jerusalem, Israel
- 245 10
- $a Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs / $c C. Schmidt, T. Babu, H. Kostrhunova, A. Timm, U. Basu, I. Ott, V. Gandin, V. Brabec, D. Gibson
- 520 9_
- $a "Multi-action" Pt(IV) derivatives of cisplatin with combretastatin A4 (CA4) bioactive ligands that are conjugated to Pt(IV) by carbonate are unique because the ligand (IC50 < 10 nM) is dramatically 1000-folds more cytotoxic than cisplatin in vitro. The Pt(IV)-CA4 prodrugs were as cytotoxic as CA4 itself, indicating that the platinum moiety probably plays an insignificant role in triggering cytotoxicity, suggesting that the Pt(IV)-CA4 complexes act as prodrugs for CA4 rather than as true multi-action prodrugs. In vivo tests (Lewis lung carcinoma) show that ctc-[Pt(NH3)2(PhB)(CA4)Cl2] inhibited tumor growth by 93% compared to CA4 (67%), cisplatin (84%), and 1:1:1 cisplatin/CA4/PhB (85%) while displaying <5% body weight loss compared to cisplatin (20%) or CA4 (10%). In this case, and perhaps with other extremely potent bioactive ligands, platinum(IV) acts merely as a self-immolative carrier triggered by reduction in the cancer cell with only a minor contribution to cytotoxicity.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
- 650 _2
- $a karboanhydrasa IV $x chemie $x metabolismus $7 D030741
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a Cricetulus $7 D003412
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a organoplatinové sloučeniny $x chemická syntéza $x chemie $x farmakologie $7 D009944
- 650 _2
- $a prekurzory léčiv $x chemická syntéza $x chemie $x farmakologie $7 D011355
- 650 _2
- $a prohibitiny $7 D000091402
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Babu, Tomer $u Institute for Drug Research, School of Pharmacy, The Hebrew University, 91120 Jerusalem, Israel
- 700 1_
- $a Kostrhunova, Hana $u Institute of Biophysics, Czech Academy of Sciences, Academy of Sciences, Kralovopolska 135, 61265 Brno, Czech Republic
- 700 1_
- $a Timm, Annika $u Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstrasse 55, 38106 Braunschweig, Germany
- 700 1_
- $a Basu, Uttara $u Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstrasse 55, 38106 Braunschweig, Germany
- 700 1_
- $a Ott, Ingo $u Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstrasse 55, 38106 Braunschweig, Germany
- 700 1_
- $a Gandin, Valentina $u Dipartimento di Scienze del Farmaco, Universita di Padova, Via Marzolo 5, 35131 Padova, Italy
- 700 1_
- $a Brabec, Viktor $u Institute of Biophysics, Czech Academy of Sciences, Academy of Sciences, Kralovopolska 135, 61265 Brno, Czech Republic $u Department of Biophysics, Faculty of Science, Palacky University in Olomouc, Slechtitelu 27, 78371 Olomouc, Czech Republic $1 https://orcid.org/0000000282331393 $7 jo20010087133
- 700 1_
- $a Gibson, Dan $u Institute for Drug Research, School of Pharmacy, The Hebrew University, 91120 Jerusalem, Israel $1 https://orcid.org/0000000216314018
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 64, č. 15 (2021), s. 11364-11378
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34342437 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171825 $b ABA008
- 999 __
- $a ok $b bmc $g 1925208 $s 1191185
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2021 $b 64 $c 15 $d 11364-11378 $e 20210803 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20230418